Drug intelligence / Profile preview

HYR04

Development stage: Phase 2
Lead developer: Tiandi Hengyi Pharmaceutical
Administration: Oral

Overview

HYR04 is a traditional Chinese medicine (TCM) capsule developed by Tiandi Hengyi for the treatment of knee osteoarthritis, specifically targeting patients with the cold-dampness obstruction pattern (寒湿痹阻证). Registered as a Class 2.3 TCM modified new drug in China, HYR04 is a clinical-stage development of the company's marketed Huoluo Xiaotong capsule (活络消痛胶囊), which is formulated from a mixture of ten herbal ingredients including Acanthopanax senticosus extract, Clematis chinensis, Angelica sinensis, processed Aconitum carmichaelii, processed Aconitum kusnezoffii, Ephedra sinica, Anemone raddeana, Salvia miltiorrhiza, processed Boswellia carterii, and processed Commiphora myrrha. HYR04 is currently undergoing Phase II clinical evaluation in China to assess its efficacy in improving knee pain and joint function.

Other names: Huoluo Xiaotong capsule活络消痛胶囊

Beyond the preview

Go deeper on HYR04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HYR04.